Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 52

1.

CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.

Kohrt HE, Houot R, Goldstein MJ, Weiskopf K, Alizadeh AA, Brody J, Müller A, Pachynski R, Czerwinski D, Coutre S, Chao MP, Chen L, Tedder TF, Levy R.

Blood. 2011 Feb 24;117(8):2423-32. doi: 10.1182/blood-2010-08-301945. Epub 2010 Dec 30.

PMID:
21193697
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Dose finding study for the use of subcutaneous recombinant interleukin-2 to augment natural killer cell numbers in an outpatient setting for stage 4 neuroblastoma after megatherapy and autologous stem-cell reinfusion.

Ladenstein R, Pötschger U, Siabalis D, Garaventa A, Bergeron C, Lewis IJ, Stein J, Kohler J, Shaw PJ, Holter W, Pistoia V, Michon J.

J Clin Oncol. 2011 Feb 1;29(4):441-8. doi: 10.1200/JCO.2009.23.5465. Epub 2010 Dec 13.

PMID:
21149662
[PubMed - indexed for MEDLINE]
Free Article
3.

Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy.

Delgado DC, Hank JA, Kolesar J, Lorentzen D, Gan J, Seo S, Kim K, Shusterman S, Gillies SD, Reisfeld RA, Yang R, Gadbaw B, DeSantes KB, London WB, Seeger RC, Maris JM, Sondel PM.

Cancer Res. 2010 Dec 1;70(23):9554-61. doi: 10.1158/0008-5472.CAN-10-2211. Epub 2010 Oct 8.

PMID:
20935224
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.

Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM; Children's Oncology Group.

N Engl J Med. 2010 Sep 30;363(14):1324-34. doi: 10.1056/NEJMoa0911123.

PMID:
20879881
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers.

Wu L, Parton A, Lu L, Adams M, Schafer P, Bartlett JB.

Cancer Immunol Immunother. 2011 Jan;60(1):61-73. doi: 10.1007/s00262-010-0919-9. Epub 2010 Sep 17.

PMID:
20848094
[PubMed - indexed for MEDLINE]
6.

NK cell terminal differentiation: correlated stepwise decrease of NKG2A and acquisition of KIRs.

Béziat V, Descours B, Parizot C, Debré P, Vieillard V.

PLoS One. 2010 Aug 6;5(8):e11966. doi: 10.1371/journal.pone.0011966.

PMID:
20700504
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Rituximab: mechanism of action.

Weiner GJ.

Semin Hematol. 2010 Apr;47(2):115-23. doi: 10.1053/j.seminhematol.2010.01.011. Review.

PMID:
20350658
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Neuroblastoma: Therapeutic strategies for a clinical enigma.

Modak S, Cheung NK.

Cancer Treat Rev. 2010 Jun;36(4):307-17. doi: 10.1016/j.ctrv.2010.02.006. Epub 2010 Mar 12. Review.

PMID:
20227189
[PubMed - indexed for MEDLINE]
9.

'Unlicensed' natural killer cells dominate the response to cytomegalovirus infection.

Orr MT, Murphy WJ, Lanier LL.

Nat Immunol. 2010 Apr;11(4):321-7. doi: 10.1038/ni.1849. Epub 2010 Feb 28.

PMID:
20190757
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.

Borgerding A, Hasenkamp J, Engelke M, Burkhart N, Trümper L, Wienands J, Glass B.

Exp Hematol. 2010 Mar;38(3):213-21. doi: 10.1016/j.exphem.2009.12.007. Epub 2010 Jan 6.

PMID:
20056126
[PubMed - indexed for MEDLINE]
11.

KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma.

Venstrom JM, Zheng J, Noor N, Danis KE, Yeh AW, Cheung IY, Dupont B, O'Reilly RJ, Cheung NK, Hsu KC.

Clin Cancer Res. 2009 Dec 1;15(23):7330-4. doi: 10.1158/1078-0432.CCR-09-1720. Epub 2009 Nov 24.

PMID:
19934297
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors.

Xu H, Cheung IY, Guo HF, Cheung NK.

Cancer Res. 2009 Aug 1;69(15):6275-81. doi: 10.1158/0008-5472.CAN-08-4517. Epub 2009 Jul 7.

PMID:
19584290
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells.

Romagné F, André P, Spee P, Zahn S, Anfossi N, Gauthier L, Capanni M, Ruggeri L, Benson DM Jr, Blaser BW, Della Chiesa M, Moretta A, Vivier E, Caligiuri MA, Velardi A, Wagtmann N.

Blood. 2009 Sep 24;114(13):2667-77. doi: 10.1182/blood-2009-02-206532. Epub 2009 Jun 24.

PMID:
19553639
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

NK cell responsiveness is tuned commensurate with the number of inhibitory receptors for self-MHC class I: the rheostat model.

Joncker NT, Fernandez NC, Treiner E, Vivier E, Raulet DH.

J Immunol. 2009 Apr 15;182(8):4572-80. doi: 10.4049/jimmunol.0803900.

PMID:
19342631
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function after T cell-depleted allogeneic hematopoietic cell transplantation.

Yu J, Venstrom JM, Liu XR, Pring J, Hasan RS, O'Reilly RJ, Hsu KC.

Blood. 2009 Apr 16;113(16):3875-84. doi: 10.1182/blood-2008-09-177055. Epub 2009 Jan 28.

PMID:
19179302
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Cutting edge: viral infection breaks NK cell tolerance to "missing self".

Sun JC, Lanier LL.

J Immunol. 2008 Dec 1;181(11):7453-7.

PMID:
19017932
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Functions of natural killer cells.

Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S.

Nat Immunol. 2008 May;9(5):503-10. doi: 10.1038/ni1582. Review.

PMID:
18425107
[PubMed - indexed for MEDLINE]
18.

Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3.

Moesta AK, Norman PJ, Yawata M, Yawata N, Gleimer M, Parham P.

J Immunol. 2008 Mar 15;180(6):3969-79.

PMID:
18322206
[PubMed - indexed for MEDLINE]
Free Article
19.

Differentiation induced by physiological and pharmacological stimuli leads to increased antigenicity of human neuroblastoma cells.

Carlson LM, Påhlman S, De Geer A, Kogner P, Levitskaya J.

Cell Res. 2008 Mar;18(3):398-411. doi: 10.1038/cr.2008.27.

PMID:
18268541
[PubMed - indexed for MEDLINE]
Free Article
20.

Hierarchy of the human natural killer cell response is determined by class and quantity of inhibitory receptors for self-HLA-B and HLA-C ligands.

Yu J, Heller G, Chewning J, Kim S, Yokoyama WM, Hsu KC.

J Immunol. 2007 Nov 1;179(9):5977-89. Erratum in: J Immunol. 2007 Dec 15;179(12):8570.

PMID:
17947671
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk